Analytical Data
-
Gene name
HLA-A*11:01&B2M&HPV16-E7(KITDFGRAK) Monomer
- Application
-
Alternative Names
HLA-A*1101 & B2M & HPV16-E7 (IVCPICSQK)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&IVCPICSQK
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*11:01/B2M/HPV16-E7 (KITDFGRAK) monomer recombinant protein is significant due to its relevance in understanding the immune response to Human Papillomavirus (HPV) and the development of potential vaccines and immunotherapies. HPV is a predominant cause of cervical and other anogenital cancers, with type 16 being one of the most oncogenic strains. The HLA-A*11:01 allele is known to present specific peptides derived from HPV E7 protein, including KITDFGRAK, to cytotoxic T lymphocytes (CTLs), playing a crucial role in the recognition and elimination of HPV-infected cells. Utilizing a recombinant protein model enables researchers to assess the interactions between the HLA molecule, beta-2 microglobulin (B2M), and the HPV E7 peptide, providing insights into T-cell receptor (TCR) recognition and activation. This research not only enhances our understanding of the antigen presentation pathway but also contributes to the design of targeted therapies and vaccines aimed at harnessing the immune system to combat HPV-related malignancies. By investigating this monomer structure, researchers aim to unravel the intricacies of T-cell responses to HPV, ultimately paving the way for innovative cancer immunotherapies.
